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Targeted therapies require cellular protein expression that meets speciﬁc requirements
that will maximize effectiveness, minimize off-target toxicities, and provide an opportu-
nity for a therapeutic effect. The receptor tyrosine kinase-like orphan receptors (ROR) are
possible targets for therapy that may meet such requirements. RORs are transmembrane
proteins that are part of the receptor tyrosine kinase (RTK) family. The RORs have been
shown to play a role in tumor-like behavior, such as cell migration and cell invasiveness
and are normally not expressed in normal adult tissue. As part of the large effort in target
discovery, ROR proteins have recently been found to be expressed in human cancers.Their
unique expression proﬁles may provide a novel class of therapeutic targets for small mol-
ecules against the kinase or for antibody-based therapies against these receptors. Being
restricted on tumor cells and not on most normal tissues, RORs are excellent targets for
the treatment of minimal residual disease, the ﬁnal hurdle in the curative approach to many
cancers, including solid tumors such as neuroblastoma. In this review, we summarize the
biology of RORs as they relate to human cancer, and highlight the therapeutic approaches
directed toward them.
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INTRODUCTION
The receptor tyrosine kinase-like orphan receptors (ROR) are
transmembrane proteins that are part of the receptor tyro-
sine kinase (RTK) family. They are related to the Trk–RTK,
muscle-speciﬁc kinase (MuSK), and neurotrophic tyrosine kinase
(NTRTK) receptor families (Masiakowski and Carroll, 1992; For-
rester et al., 1999). The ROR1 and ROR2 genes, ﬁrst identiﬁed
in a neuroblastoma cell line, are located on chromosomes 1 and
9, respectively, both encoding a 104-kDa proteins (Reddy et al.,
1997). Homozygous mutations in ROR2 have been shown to be
responsible for the Robinow syndrome, a skeletal dysplasia syn-
drome characterized by generalized limb shortening, segmental
defects of the spine, and dysmorphic facial appearance, while
heterozygous mutations have been found in patients with dom-
inant brachydactyly B1, characterized by terminal deﬁciency of
ﬁngers and toes (Afzal et al., 2000; Afzal and Jeffery, 2003). The
RORs are made up of an extracellular domain consisting of
an immunoglobulin-like motif, a cysteine-rich frizzled domain,
a kringle domain, and an intracellular tyrosine kinase domain
(Figure 1). They were named orphan receptors because their
endogenous ligands had not yet been discovered. However, recent
studies have shown that the frizzle-domain of ROR2 associates
with the Wnt5a protein and is involved with the non-canonical
Wnt pathways (McDonald and Silver, 2009), but the deﬁnitive
ligand for ROR1 is yet to be determined. The RORs have been
shown to play a role in establishing cellular polarity (Green et al.,
2008) and in tumor-like behavior, such as cell migration and cell
invasiveness (Morioka et al., 2009). These receptors are normally
expressed at high levels during development, playing a key role in
skeletal and neural organogenesis, but then become repressed in
adult tissues (Al-Shawi et al., 2001). Interestingly, ROR1 is upregu-
lated in B-cell chronic lymphocytic leukemia (B-CLL; Baskar et al.,
2008), B-cell acute lymphocytic leukemia (B-ALL; Shabani et al.,
2008), andmantle cell leukemia (MCL;Hudecek et al., 2010),while
ROR2 is overexpressed in osteosarcoma (OS; Morioka et al., 2009),
and renal cell carcinoma (RCC; Wright et al., 2009). This unique
expressionproﬁlemayprovide anovel family of therapeutic targets
for small molecules against the kinase or for antibody-based ther-
apies against these receptors (Hudecek et al., 2010). In this review,
we summarize the biology of RORs as they relate to human cancer,
and highlight the therapeutic approaches directed toward them.
RECEPTOR PROPERTIES OF ROR PROTEINS
Receptor tyrosine kinase-like orphan receptors are membrane
proteins composed of three extracellular domains, one trans-
membrane domain, and one intracellular domain. Comparative
genomic studies have found that the three extracellular domains
and the one intracellular domain are conserved from drosophila
and Caenorhabditis elegans to mice to humans (Figure 1; Katoh,
2005). Two different splice variants have been identiﬁed for ROR1,
one lacking all the extracellular domains known as truncated-
ROR1 (t-ROR1) andone lackingboth the intracellular domain and
transmembrane domains (Reddy et al., 1996). So far most studies
have focused on the full length form of ROR1. Some reports have
claimed that the intracellular tyrosine kinase domain lacks biolog-
ical activity (Gentile et al., 2011), while others suggest its critical
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FIGURE 1 | Structure of receptor tyrosine kinase-like orphan receptor
(ROR) in different species.Type 1 receptor tyrosine kinase evolutionarily
conserved, co-receptor with Frizzled-2/4, with immunoglobulin (Ig) domain,
cysteine-rich domain (CRD), and Kringle domain. The intracellular portion
contains tyrosine kinase (TK) domain, proline-rich domain (PRD) ﬂanked by
Ser/Thr rich domains (S/TRD1 and 2; Green et al., 2008; Minami et al., 2010).
role in signal transduction to downstream proteins (Mikels et al.,
2009). The kinase activity of ROR2, on the other hand, has been
well-established (Kani et al., 2004;Yamamoto et al., 2007; Liu et al.,
2008). We will discuss ROR2 kinase activity in more details later.
Intriguingly, vertebrate ROR proteins seem to have acquired
additional cytosolic domains important for downstream signaling.
In addition to the tyrosine kinase domain,vertebrateRORs contain
a serine/threonine-rich domain (S/TRD1), a proline-rich domain
(PRD), and an additional serine/threonine-rich domain (S/TRD2;
Minami et al., 2010). Current studies have mainly focused on
the extracellular cysteine-rich domain (CRD) in Frizzle since this
domain has been shown to bind Wnt ligands for other cell sur-
face receptors (Rehn et al., 1998). Studies in drosophila and mice
have identiﬁed Wnt5a to be a ligand for ROR2 by comparing
expression levels and loss-of-function phenotypes between ROR2
and Wnt5a homologs (Oishi et al., 2003; Green et al., 2007). Co-
expression and co-immunoprecipitation studies have shown that
Wnt5b could also bind to ROR2 in osteosarcoma cells (Morioka
et al., 2009). Yet, the deﬁnitive ligand for ROR1 is still uncertain.
The properties of the immunoglobulin domain and kringle extra-
cellular domains have not beenwell characterized; thus, the under-
standing of the key biologic function of ROR proteins remains
incomplete.
Mikels et al. (2009) has shown that ROR2 and its ligand,
Wnt5a might be involved in the non-canonical Wnt pathway.
In vivo studies in mice have shown that when mROR2 or Wnt5a
expression is knocked down,Wnt/β-catenin signaling is enhanced,
consistent with ROR2’s function as an inhibitor of canonical Wnt
pathways. Furthermore, the CRD, immunoglobulin-like extracel-
lular domains, and intracellular tyrosine kinase domain all seem
necessary for inhibition to occur, since truncated forms of ROR2
lose their inhibitory function. The canonical pathway could also be
inhibited through the Wnt/calcium pathway via CamKII (Ishitani
et al., 2003).WhenWnt5a binds toROR2,CamKII is activated, and
through the mitogen-activated protein kinase (MAPK) pathway,
negatively regulates the canonical Wnt/β-catenin signaling. These
inhibitory pathways against canonical signaling may function as
fail-safes to prevent aberrant β-catenin-induced gene expression
from cancer-promoting activity. This tumor-suppressing effect
has been proposed for high risk neuroblastoma since Wnt5a is
down-regulated in neuroblastoma cell lines (Blanc et al., 2005).
EXPRESSION PATTERN DURING NORMAL DEVELOPMENT
Receptor tyrosine kinase-like orphan receptors play a signiﬁ-
cant role in embryonic development. Studies of ROR orthologs
found in C. elegans, Drosophila melanogaster, Xenopus, and mice
have mapped the expression proﬁles of RORs during develop-
ment demonstrating a striking conservation during evolution to
human (Wilson et al., 1993; Yoda et al., 2003). When the C. ele-
gans ROR ortholog, CAM-1, was mutated, normal migration of
canal-associated neurons was disrupted, suggesting a critical role
of RORs in neuronal development. In mice, mRor1 and mRor2
are highly expressed during the early stages of development, rep-
resented in most of the major systems in tissues derived from
all three germ layers, but most prominently seen in neural crest
cells and their derivatives, such as special sense organs (Al-Shawi
et al., 2001). While mRor2 is broadly expressed in the developing
nervous system, mRor1 is restricted primarily to the head mes-
enchyme during fetal development (Oishi et al., 1999; Al-Shawi
et al., 2001). In earlier report, knockout phenotype could not
be studied since mRor1−/− mice do not survive beyond 24 h of
life, dying from respiratory dysfunction, highly suggestive of the
role of ROR1 in normal lung development (Al-Shawi et al., 2001;
Nomi et al., 2001). A recent study showed that ROR1−/− mutants
could survive,butwith growth retardation.Thesemutantmicehad
multiple skeletal defects and urogenital abnormalities, resulting in
reduced life expectancy and female infertility (Lyashenko et al.,
2010). Ror2-deﬁcient mice are viable, but have well-deﬁned skele-
tal and heart abnormalities, modulated to some extent by mRor1
(Nomi et al., 2001). Although RORs are critical during normal
development, they become undetectable in normal adult tissues,
including humans. ROR1 is not expressed in mature B-cells, T-
cells, monocytes, and natural killer cells; but transient expression
was found at intermediate stage of normal B-cell development
and the earliest B-cell precursors in the bone marrow. ROR1 was
expressed in undifferentiated ES cells and expression was down-
regulated upon differentiation in conditioned medium (Hudecek
et al., 2010).
ABERRANT EXPRESSION OF RORs IN CANCER
Although expression of RORs is embryonal, limited to the normal
stages of development, their aberrant expression in certain cancers
is of interest. As an oncofetal antigen, high levels of ROR1 expres-
sion have been found as mRNA and as protein in B-CLL (Baskar
et al., 2008; Daneshmanesh et al., 2008; Fukuda et al., 2008), while
totally absent in healthy donor peripheral bloodmononuclear cells
(PBMC) and all other normal tissues except for tonsillar B-cells
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics April 2012 | Volume 2 | Article 34 | 2
Rebagay et al. Targeted therapy using ROR1/ROR2
(Daneshmanesh et al., 2008). ROR1 is preferentially expressed over
ROR2 in B-CLL cells. Furthermore, it is constitutively expressed
on B-CLL cells despite B-cell activation via CD40L and IL-4. The
pattern of expression did not differ between IgVH mutated and
unmutated B-CLL cases (Daneshmanesh et al., 2008). In addition
to B-CLL, ROR1 was also upregulated at the mRNA level in B-ALL
(Shabani et al., 2008). ROR1 was only overexpressed in mature
leukemic B-cells but not in immature forms (Shabani et al., 2008).
IL-6 could regulate ROR1 expression through Stat3 inCLL cells (Li
et al., 2010). ROR1was extensivelymodiﬁedbyN-linked glycosyla-
tion (Kaucka et al., 2011), producing variants with electrophoretic
migration of approximately 100, 115, and 130 kDa. Inhibition of
glycosylation interfered with cell surface localization of the 130-
kDa variant of ROR1 and prevented Ror1-induced formation of
ﬁlopodia. The 130-kDa formwasmono-ubiquitinated.Due to var-
ious glycosylation patterns, ROR1 from individual CLL patients
showed striking differences in the electrophoretic mobility.
Among solid tumors, ROR1 had increased expression in gastric
carcinoma and non-small cell carcinoma cell lines (Gentile et al.,
2011). Here ROR1 functions as a pseudokinase crucial for Met-
driven tumorigenesis. On the other hand, ROR2 was upregulated
in osteosarcoma and RCC cell lines, as well as primary tumors,
while not on normal tissues except for thyroid and stomach
(Morioka et al., 2009; Wright et al., 2009). In sum, this differential
expression of RORs among human cancers and the low to absent
expression in normal tissues support their potential as therapeutic
targets both in leukemia and in select solid tumors. In neuroblas-
toma, ROR1 and ROR2 were expressed in all tumor stages. Among
patients, high levels of ROR1 or ROR2 gene expression correlated
signiﬁcantly with poorer survival (Asgharzadeh et al., 2006).
ONCOGENIC PROPERTIES OF RORs
Although in neuroblastoma, Wnt5a/ROR signaling was hypoth-
esized to have tumor-suppressing effects, several studies using
other human cancers have shown the complete opposite, in which
Wnt/ROR signaling induces tumor proliferation and tumor inva-
siveness. The ROR2/Wnt5a pathway has been shown to involve
signaling through Wnt-c-Jun N-terminal kinase (Jnk) via acti-
vation of the actin binding protein, ﬁlamin A, which binds to
the PRD intracellular domain in vertebrates (Oishi et al., 2003;
Nomachi et al., 2008). Through activation of this pathway, mice
ﬁbroblasts could be induced to undergo cellular migration and
invasion, features pathognomonic of malignancy. siRNA studies
of osteosarcoma cells have shown a strong correlation between
ROR2 knockdown and decreased cell migration in transwell assays
(Enomoto et al., 2009). Furthermore, introduction of ROR2 into
human ﬁbroblast and kidney cells greatly enhanced the invasive
activity of these cells. When knocked down by siRNA, the viability
and survival of these cells decreased (Morioka et al., 2009). This
effect of gene knockdown was also seen in RCC cells, where the
suppression of ROR2 expression not only decreased the migration
of RCC cells, but also inhibited anchorage-independent growth
in soft agar and growth in an orthotopic xenograft mouse model
(Wright et al., 2009). Furthermore, ROR2 knockdown by siRNA
inhibited invasion of melanoma cells in a murine in vivo tumor
model (O’Connell et al., 2010). All these studies implies ROR2 role
in tumorigenesis and progression.
ROR1 was reported to be upregulated in B-CLL. Studies con-
ducted by Choudhury et al. (2010) showed that silencing of
ROR1 with siRNA results in apoptosis of primary B-CLL cells
from patients, but not PBMC from healthy donors. It was found
that ROR1 is constitutively phosphorylated in the B-CLL cells of
al patients tested. Using a siRNA screening method, ROR1 was
identiﬁed as a key factor for survival of t (1:19) acute lymphoblas-
tic leukemia (ALL) primary cells and cell lines in vitro (Bicocca
et al., 2011). Interestingly, ROR1 was elevated only in the t (1:19)
ALL and not other ALL subtypes. It remains to be investigated
whether ROR1 is phosphorylated in t (1:19) ALL cells. In a trans-
genic mice model, studies suggested that ROR1 can accelerate the
development of CLL. In these studies, transgenic mice express-
ing human ROR1 under control of a B-cell speciﬁc promoter
developed hROR1+/CD5+/B220 low B-cell leukemia resembling
human CLL at 15–18 months of age. These human ROR1 trans-
genic mice were further crossed with TCL1 transgenic mice, which
at 7 months of age develop CD5 +B220 low leukemia B-cells.
The F1 mice with both transgenes (hROR1×TCL1) developed
hROR1+/CD5+/B220 low leukemia B-cell CLL at a signiﬁcantly
youngermedian age thandid littermate-controlmice having either
transgene alone (Cui et al., 2011).
To further explore the invasive character of these cells upon
ROR activation, invadopodia, and extracellular matrix (ECM)
remodeling proteins, such as matrix metalloproteinases (MMPs),
were studied to see if these components were co-expressed with
ROR. In order for cells to migrate, the ECM has to be remodeled
to allow for the cell to migrate through the extracellular milieu.
Invadopodia are actin-rich protrusions that degrade and extend
into the ECM, remodeling the ECM for tumor migration and
invasion (Bowden et al., 1999), while MMPs are enzymes that
degrade collagen and other components of the ECM. Through
immunostaining and ECM degrading assays, ROR2 was seen to
be concentrated in regions where invadopodia were located, as
determined by the location of cortactin, an essential component
of invadopodia that is expressed in areas where the ECM has
been degraded (Enomoto et al., 2009). Furthermore, a comparison
between severalMMPs andROR2 expression in osteosarcoma cells
was studied and found that when ROR2 was silenced via transfec-
tion of siROR2, MMP13, a collagenase, was also decreased. The
same effect was seen when siWnt5a was introduced into OS cells,
suggesting that MMP13 is activated through Wnt5a/ROR2 sig-
naling (Enomoto et al., 2009; Minami et al., 2010). Staining of
invadopodia for MMP13 also indicated its presence in this ECM
remodeling complex.Closer analysis of the signaling pathway indi-
cated that the tyrosine kinase domain of ROR2 was essential for
MMP13 activation and subsequent ECM remodeling and that Src-
family protein tyrosine kinases (SFKs), a series of kinases shown to
play an essential role in invadopodia production (Weaver, 2006),
were shown to be activated through Wnt5a/ROR2 signaling. This
then suggested that Wnt5a/ROR2 signaling activated a SFK, lead-
ing to subsequent activation of MMP13, overall leading to ECM
remodeling to allow for tumor migration and invasion. A sim-
ilar ﬁnding was found in RCC cells, in which ROR2 regulated
MMP2, shown to be overexpressed in many metastatic cancers
(Kurban et al., 2006) and play a important role in the renal tubu-
lar cell epithelial to mesenchymal transformation during wound
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healing, leading to ECM remodeling and subsequent invasive
growth (Wright et al., 2009).
THERAPEUTIC APPROACH AGAINST ROR
SMALL MOLECULE INHIBITORS
Given their restricted tissue distribution and implication in cancer,
RORs are potential targets for cancer therapy (see Table 1). The
TK domain of RORs is homologous to the discoidin-like domain
receptor (Ddr),muscle-speciﬁc kinase (MuSK), and most of all, to
the tropomyosin receptor kinase (Trk) family of receptors (Masi-
akowski and Carroll, 1992; Green et al., 2008). These receptors
recognize the Src homology domain 2 (SH2) on phosphotyro-
sine substrates that constitute phosphorylation sites that lead to
downstream transduction of the signal (Sadowski et al., 1986).
Furthermore, SH3 substrates recognize PRDs, which are found in
vertebrate ROR proteins. Since these domains are very speciﬁc for
interaction with the phosphorylated portions of the TK domain,
blocking their activity could be an effective way to truncate the sig-
nal transduction responsible for oncogenesis (Vidal et al., 2001).
However, recent work (Gentile et al., 2011) on the tyrosine kinase
domain of ROR1 showed that ROR1 is a pseudokinase. Overex-
pression of ROR1 failed to lead to kinase autophosphorylation,nor
was it able to phosphorylate exogenous substrates. Moreover, the
intracellular kinase domain of ROR1 contains amino acid substi-
tutions in positions known to be critical for the enzymatic function
of tyrosine kinase. On the contrary, constitutively activated MET
receptor tyrosine kinase leads to ROR1 phosphorylation in gas-
tric carcinoma cells (HS746T) and non-small cell lung carcinoma
cells (NCI-H1993). Knockdown of ROR1 by siRNA in these two
cell lines induces apoptosis in vitro and inhibits tumor growth in
mouse tumor models. Noticeably, ROR1 knockdown has no effect
on cell survival in cancer cells where ROR1 is overexpressed but
not phosphorylated.
It was reported that in t (1:19) ALL cells, combination of ROR1
knockdown and a kinase inhibitor, dasatinib, resulted in additive
impairment of cell viability comparedwith dasatinib alone, imply-
ing that therapies blocking ROR1 function might sensitize cancer
cells to small molecule kinase inhibitors. Dasatinib was known to
inhibit the kinase activities of Bruton’s tyrosine kinase (BTK) and
tyrosine-protein kinase Lyn, which in turn leads to downregulat-
ing activity of AKT. In support of the hypothesis that ROR1 also
serve to regulate AKT activity, ROR1 knockdown results in AKT
inhibition in t (1:19) ALL cells (Bicocca et al., 2011).
The kinase activity of ROR2 is better understood. Using
HEK293 transient expression system as a model system, Kani et
al. has shown that ROR2 is phosphorylated by casein kinase Iε, a
crucial regulator of the canonical Wnt signaling. Casein kinase Iε
phosphorylates ROR2 on serine/threonine residues, which in turn
resulted in autophosphorylation of ROR2 on tyrosine residues.
Moreover, phosphorylated ROR2 might further phosphorylate G
protein-coupled receptor kinase 2 (Kani et al., 2004). It was later
shown in NIH3T3 and HeLa-S3 cells that simulation with Wnt5a
results in ROR2 phosphorylation on serine/threonine residues.
And this phosphorylation is mediated by GSK-3α (and GSK-3β;
Yamamoto et al., 2007). Interestingly, Liu et al. (2008) found
in human U2OS osteosarcoma cells that Wnt5a was able to
induce homodimerization of ROR2 and autophosphorylation of
its tyrosine residues without phosphorylation of serine/threonine
residues. However, despite the strong evidence of ROR2 involve-
ment in tumorigenesis andprogress, there are nopublished reports
on small molecule inhibitors against ROR2.
ANTIBODY-BASED TARGETED THERAPY
As surface receptors, RORs are potential targets for monoclonal
antibodies (MoAb). Among non-hematopoietic tissues, only adi-
pose tissue express cell surface ROR1 (Baskar et al., 2008). The
Table 1 | Summary of evidence for human ROR1/2 as cancer therapeutic targets.
Properties Human ROR1 Human ROR2 Reference
Expression in adult tissues Adipose tissuea Thyroid and stomachb Baskar et al. (2008), Morioka et al. (2009)
Genetic diseases linked to gene
mutation
ND Brachydactyly type B and
Robinow syndrome
Schwabe et al. (2000), van Bokhoven et al. (2000)
Ligand ND Wnt5a Liu et al. (2008), Maeda et al. (2012)
Tyrosine kinase activity Pseudokinase Yes Gentile et al. (2011), Liu et al. (2008), Kani et al.
(2004), Yamamoto et al. (2007)
Cancer types with ROR
overexpression
B-CLL, ALL,
neuroblastoma, breast
cancer, renal cancer
Osteosarcoma, melanoma,
renal cell carcinoma,
leiomyosarcoma,
gastrointestinal stromal
tumor, and oral cancer
Baskar et al. (2008), Shabani et al. (2008),
Asgharzadeh et al. (2006), Zhang et al. (2012),
Rabbani et al. (2010), Morioka et al. (2009),
O’Connell et al. (2010),Wright et al. (2009), Edris
et al. (2012), Kobayashi et al. (2009)
Inhibition of cancer cell
proliferation/invasion by siRNA
Yes Yes Choudhury et al. (2010), Wright et al. (2009),
O’Connell et al. (2010)
In vivo inhibition of tumor
growth/invasion by siRNA/mAb
Yes Yes Cui et al. (2011), Gentile et al. (2011), Zhang et al.
(2012),Wright et al. (2009), O’Connell et al. (2010)
aProtein expression examined by Western blot. Cell surface ROR1 only. It remains possible that cell surface ROR1 is expressed at very low levels in testis, uterus,
lung, bladder, and colon.
bmRNA expression examined by Northern blot. Very weak expression signals were detected in thyroid and stomach.
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restricted pattern of expression among normal tissues makes
ROR1 an attractive target for MoAbs. High afﬁnity MoAb have
been derived from a chimeric rabbit/human Fab library and
applied to the CLL and MCL lymphoma preclinical models (Yang
et al., 2011). These antibodies have rabbit variable domains and
human constant domains. Afﬁnities of the Fab by BIACORE
ranged from 0.56 to 8.8 nM. As full IgG1, the virtual afﬁnities
were 0.04–0.7 nM.Antibodies with the highest afﬁnity and slowest
rate of internalization could mediate antibody-dependent cell-
mediated cytotoxicity (ADCC), but not complement mediated
cytotoxicity (CDC). Using lymphoma cell line as target, ADCC
was observed only for the high afﬁnity antibody at 5 μg/ml, sub-
stantially weaker than anti-CD20 antibody rituximab. Antibody
internalization appeared slower with the high afﬁnity antibody.
None of the antibodies induced apoptosis in lymphoma cells. The
advantage of these antibodies compared to other therapeutic B-cell
speciﬁc MoAbs is the absence of ROR1 in mature B-cells (Hude-
cek et al., 2010). However, given the relatively low cell surface
density, ROR1 was proposed as a preferred target for armed rather
than naked MoAb (Yang et al., 2011). Since ROR1 mediates partial
internalization of bound antibody by endocytosis, it also provides
a means to deliver cytotoxic agents into tumor cells (Baskar et al.,
2008).
Other efforts, however, identiﬁed ROR1 MoAbs that are cyto-
toxic to hROR1-expressing leukemia cells (Cui et al., 2011;
Daneshmanesh et al., 2012). In one study, over 70 unique
mAbs against human ROR1 extracellular domain were generated
through immunizing mice with various formats of full length
hROR1–ECD peptides. Most mAbs recognize epitopes within the
ROR1 Ig-like domain; others recognize epitopes within the kringle
domain. One mAb binds to a unique epitope between the Ig
and CRD domain, and is directly cytotoxic to hROR1-expressing
leukemia cells in vitro. This mAb can also signiﬁcantly decrease
the basal levels of phosphorylated AKT in primary CLL cells and
hROR1-expressing leukemic cells. Moreover, treatment of this
mAb signiﬁcantly decreased the number of primary CLL cells
transferred into the peritoneal cavity of NSG mice, and inhibited
CLL cell engraftment in the hROR1×TCL1 double transgenic
adoptive transfer model mentioned previously in the review. CDC
activity against primary CLL cells and hROR1-expressing can-
cer cell lines was also observed for this mAb. In the other study,
Mellstedt’ lab has generated ﬁve mouse by immunizing 15- to 23-
amino-acid-long peptides derived from Ig domain, CRD domain,
and kringle domain of human ROR1. All the ﬁve mAbs induce
apoptosis of primary B-CLL cells but not of normal B-cells. Most
effectivewere twomAbs against CRDand kringle domains, respec-
tively. They showed signiﬁcant superiority to rituximab. Twoof the
mAbs induced CDC similar to that of rituximab, and one mAb
against the kringle domain showed ADCC activity against ROR1-
expressing cancer cells. The discrepancy among the three studies
might be explained by the different binding epitope of unique
hROR1-speciﬁc MoAbs. Table 2 summarizes reported studies of
ROR1 MoAbs.
Another approach to overcome the low receptor density of
ROR1 was to exploit T-cells. By genetic modiﬁcation, T-cells can
be made to express a chimeric antigen receptor (CAR) speciﬁc
for ROR1, retargeting T-cell-mediated cytotoxicity against tumor
cells (Hudecek et al., 2010). Since these CD8+ modiﬁed T-cells
are efﬁcient killers, probably requiring few target antigens, and
no longer restricted to HLA or HLA type, this approach can
potentially tackle three signiﬁcant issues simultaneously, i.e., low
target density, low HLA expression, and HLA type restriction
of natural T cell epitopes. ROR1–CAR transduced T-cells efﬁ-
ciently lysed primary B-CLL, primary MCL, and ROR1-positive
tumor cell lines including the rare subset of CLL cells that efﬂux
chemotherapy, but not normal resting or activated B-cells. These
T-cells also produced effector cytokines including TNF-α, IFN-
γ, and IL-2, and were capable of proliferating in response to
ROR1-expressing tumor cells (Hudecek et al., 2010). Whether
the T-cells were derived from normal volunteers or from CLL
patients, CAR-modiﬁcation made them equally effective against
ROR1-positive targets. Another obvious alternative may be the
use of bispeciﬁc antibodies such as Bispeciﬁc T-cell engaging anti-
bodies (BiTE; Bargou et al., 2008; Choi et al., 2011). However, for
Table 2 | Biological activity of ROR1-specific MoAbs against human primary chronic lymphocytic leukemia (CLL).
Reference Antibody Epitoped Affinity (KD) ADCC CDC Apoptosis Internalization Inhibition of tumor
growth (in vivo)
Daneshmanesh et al. (2012) 3B8 (IgMa) Ig ND ND No Yes ND ND
1C11 (IgMa) CRD ND ND No Yes ND ND
1D8 (IgG1a) CRD ND ND Yes Yes ND ND
4A7 (IgG1a) KNG ND Yes Yes Yes ND ND
4C10 (IgMa) KNG ND ND No Yes ND ND
Yang et al. (2011) R11 (IgG1b) KNG 0.19 nM No No No Strong ND
R12 (IgG1b) Ig/CRD 0.11 nM Yes No No Modest ND
Y31 (IgG1b) CRD/KNG 0.71 nM No No No Strong ND
Cui et al. (2011) UC D10a,c Ig/CRD 41nM ND Yes Yes ND Yes
aMouse antibody.
bRabbit/human chimeric IgG1 antibody.
cTarget cells for biological activity includes ROR1-positive leukemia cell lines, in addition to primary CLL cells.
dRefer to Figure 1 for domain description.
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monovalent constructs, high afﬁnity ROR-speciﬁc antibodies may
be needed.
FUTURE DIRECTIONS
As part of the large effort in target discovery, ROR proteins have
recently been characterized as unique markers for several cancers.
Being restricted on tumor cells and not on most normal tissues,
RORs are excellent targets for the treatment of minimal residual
disease, the ﬁnal hurdle in the curative approach to many cancers,
including solid tumors such as neuroblastoma. Currently, ROR1
is used as a diagnostic tool for CLL (Uhrmacher et al., 2011), and
is likely a critical receptor in the evolution of other non-Hodgkin
lymphomas, such asMCLandmarginal zone lymphoma (Hudecek
et al., 2010; Barna et al., 2011). Most attention has been focused
on ROR1 for targeted measures (Gentile et al., 2011), however
ROR2 remains a viable target candidate. A deeper understand-
ing of the signaling pathway of both ROR1 and ROR2 will go
a long way in designing rational therapy. Clarity on the dual-
ity of Wnt5a signaling as a tumor-suppressor and an oncogenic
protein is needed, with full characterization of the cellular envi-
ronment and conditions that promote either fate. Several reports
point to the receptor proﬁle on the cell surface as a marker to
determine which Wnt signal dictates the cell, showing that Wnt5a
could induce clathrin-mediated internalization when bound to a
Frizzle2-containing receptor, suppressing the ability ofWnt3a, also
a putative ligand for ROR2 that leads to canonical β-catenin accu-
mulation, to bind to ROR2. This establishes a dose-dependent
environment for whichever Wnt ligand can ﬁrst bind to ROR2
and dictates the signaling pathway (Liu et al., 2008; Sato et al.,
2010). There is further suggestion that the presence of the Frizzle4-
containing receptor could also bind Wnt5a and induce the canon-
ical β-catenin-dependent pathway, suggesting that Wnt signaling
is dictated by receptor availability as opposed to the Wnt ligands
themselves (Mikels and Nusse, 2006). This interesting dichotomy
could provide new insight into the mechanism behind tumor
metastasis and invasion via Wnt/ROR signaling. Another issue
that needs to be further resolved is to determine the number of
ROR molecules present on the cell surface in order for future anti-
body therapies to be effective. For efﬁcient antibody-dependent
cell-mediated cytotoxicity (ADCC) and complement dependent
cytotoxicity (CDC), there needs to be enough molecules of the
antigen present on the cell surface to actively engage these cellular
processes. In B-CLL cells and neuroblastoma, the antigen density
was on the lower end around 103–104 molecules per cell, thereby
limiting the capabilities of ADCC and CDC (Baskar et al., 2008;
Yang et al., 2011). On the other hand, the antigen density needed
for NK or T-cell-mediated cytotoxicities could be much less strin-
gent (Tassev et al., 2012). Strategies to increase RORs expression
on tumor cells using cytokines may be a possible solution. Alter-
natively, highly potent toxin immunoconjugates, radioimmuno-
conjugates, bispeciﬁc antibodies, or CAR-retargeted T-cells or NK
cells could overcome these antigen density limitations.
ACKNOWLEDGMENTS
We would like to thank Joseph Olechnowicz for editing this
manuscript and Chelsea Chang for Figure 1 drawing.
REFERENCES
Afzal, A. R., and Jeffery, S. (2003). One
gene, two phenotypes: ROR2 muta-
tions in autosomal recessive Robi-
now syndrome and autosomal dom-
inant brachydactyly type B. Hum.
Mutat. 22, 1–11.
Afzal, A. R., Rajab, A., Fenske, C. D.,
Oldridge, M., Elanko, N., Ternes-
Pereira, E., Tuysuz, B., Murday, V.
A., Patton, M. A., Wilkie, A. O., and
Jeffery, S. (2000). Recessive Robi-
now syndrome, allelic to dominant
brachydactyly type B, is caused by
mutation of ROR2. Nat. Genet. 25,
419–422.
Al-Shawi, R., Ashton, S. V., Underwood,
C., and Simons, J. P. (2001). Expres-
sion of the Ror1 and Ror2 receptor
tyrosine kinase genes during mouse
development. Dev. Genes Evol. 211,
161–171.
Asgharzadeh, S., Pique-Regi, R., Sposto,
R., Wang, H., Yang, Y., Shimada,
H., Matthay, K., Buckley, J., Ortega,
A., and Seeger, R. C. (2006). Prog-
nostic signiﬁcance of gene expres-
sion proﬁles of metastatic neurob-
lastomas lacking MYCN gene ampli-
ﬁcation. J. Natl. Cancer Inst. 98,
1193–1203.
Bargou, R., Leo, E., Zugmaier, G.,
Klinger, M., Goebeler, M., Knop, S.,
Noppeney, R., Viardot, A., Hess, G.,
Schuler, M., Einsele, H., Brandl, C.,
Wolf, A., Kirchinger, P., Klappers, P.,
Schmidt, M., Riethmuller, G., Rein-
hardt, C., Baeuerle, P. A., and Kufer,
P. (2008). Tumor regression in can-
cer patients by very low doses of a T
cell-engaging antibody. Science 321,
974–977.
Barna, G., Mihalik, R., Timar, B.,
Tombol, J., Csende, Z., Sebestyen,A.,
Bodor, C., Csernus, B., Reiniger, L.,
Petak, I., and Matolcsy, A. (2011).
ROR1 expression is not a unique
marker of CLL. Hematol. Oncol. 29,
17–21.
Baskar, S., Kwong, K. Y., Hofer, T.,
Levy, J. M., Kennedy, M. G., Lee,
E., Staudt, L. M., Wilson, W. H.,
Wiestner, A., and Rader, C. (2008).
Unique cell surface expression of
receptor tyrosine kinase ROR1 in
human B-cell chronic lymphocytic
leukemia. Clin. Cancer Res. 14,
396–404.
Bicocca, V. T., Chang, B. H., Muschen,
M., Druker, B. J., and Tyner, J.
W. (2011). “Compensatory signaling
from ROR1 and the pre-B cell recep-
tor promote survival of t(1;19) acute
lymphoblastic leukemia blood,” in
ASH Annual Meeting Abstracts, San
Diego, Vol. 118, 2466.
Blanc, E., Roux, G. L., Benard, J., and
Raguenez,G. (2005). Lowexpression
of Wnt-5a gene is associated with
high-risk neuroblastoma. Oncogene
24, 1277–1283.
Bowden, E. T., Barth, M., Thomas, D.,
Glazer, R. I., and Mueller, S. C.
(1999).An invasion-related complex
of cortactin, paxillin and PKCmu
associates with invadopodia at sites
of extracellular matrix degradation.
Oncogene 18, 4440–4449.
Choi, B. D., Cai, M., Bigner, D. D.,
Mehta, A. I., Kuan, C. T., and Samp-
son, J. H. (2011). Bispeciﬁc anti-
bodies engage T cells for antitumor
immunotherapy. Expert Opin. Biol.
Ther. 11, 843–853.
Choudhury, A., Derkow, K., Danesh-
manesh, A. H., Mikaelsson, E., Kiaii,
S., Kokhaei, P., Osterborg, A., and
Mellstedt, H. (2010). Silencing of
ROR1 and FMOD with siRNA
results in apoptosis of CLL cells. Br.
J. Haematol. 151, 327–335.
Cui, B., Widhopf, G. F. II., Martinez, J.
Y. D., Avery, E., Zhang, S., Chen, L.,
Wu, R., Wu, C. C. N., Prussak, C.,
and Kipps, T. J. (2011). “Targeting
of chronic lymphocytic leukemia B
cells with a novel monoclonal anti-
body to ror1 blood,” in ASH Annual
Meeting Abstracts, San Diego, Vol.
118, 984.
Daneshmanesh, A. H., Hojjat-Farsangi,
M., Khan, A. S., Jeddi-Tehrani, M.,
Akhondi,M. M., Bayat,A.A.,Ghods,
R., Mahmoudi, A. R., Hadavi, R.,
Osterborg, A., Shokri, F., Rabbani,
H., and Mellstedt, H. (2012).
Monoclonal antibodies against
ROR1 induce apoptosis of chronic
lymphocytic leukemia (CLL)
cells. Leukemia. doi:10.1038/leu.
2011.362. [Epub ahead of
print].
Daneshmanesh, A. H., Mikaelsson, E.,
Jeddi-Tehrani, M., Bayat, A. A.,
Ghods, R., Ostadkarampour, M.,
Akhondi, M., Lagercrantz, S., Lars-
son, C., Osterborg, A., Shokri, F.,
Mellstedt, H., and Rabbani, H.
(2008). Ror1, a cell surface recep-
tor tyrosine kinase is expressed
in chronic lymphocytic leukemia
and may serve as a putative tar-
get for therapy. Int. J. Cancer 123,
1190–1195.
Edris, B., Espinosa, I., Mühlenberg, T.,
Mikels, A., Lee, C. H., Steigen, S.
E., Zhu, S., Montgomery, K. D.,
Lazar, A. J., Lev, D., Fletcher, J. A.,
Beck, A. H., West, R. B., Nusse, R.,
and van de Rijn, M. (2012). ROR2
is a novel prognostic biomarker
and a potential therapeutic target
in leiomyosarcoma and gastroin-
testinal stromal tumour. J. Pathol.
doi:10.1002/path.3986. [Epub ahead
of print].
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics April 2012 | Volume 2 | Article 34 | 6
Rebagay et al. Targeted therapy using ROR1/ROR2
Enomoto, M., Hayakawa, S.,
Itsukushima, S., Ren, D. Y., Matsuo,
M., Tamada, K., Oneyama, C.,
Okada, M., Takumi, T., Nishita, M.,
andMinami,Y. (2009).Autonomous
regulation of osteosarcoma cell inva-
siveness by Wnt5a/Ror2 signaling.
Oncogene 28, 3197–3208.
Forrester, W. C., Dell, M., Perens, E.,
and Garriga, G. (1999). A C. elegans
Ror receptor tyrosine kinase regu-
lates cell motility and asymmetric
cell division. Nature 400, 881–885.
Fukuda, T., Chen, L., Endo, T., Tang, L.,
Lu,D., Castro, J. E.,Widhopf,G. F. II,
Rassenti, L. Z., Cantwell, M. J., Prus-
sak, C. E., Carson, D. A., and Kipps,
T. J. (2008). Antisera induced by
infusions of autologous Ad-CD154-
leukemia B cells identify ROR1 as an
oncofetal antigen and receptor for
Wnt5a. Proc. Natl. Acad. Sci. U.S.A.
105, 3047–3052.
Gentile, A., Lazzari, L., Benvenuti, S.,
Trusolino, L., and Comoglio, P. M.
(2011). Ror1 is a pseudokinase that
is crucial for Met-driven tumorigen-
esis. Cancer Res. 71, 3132–3141.
Green, J. L., Inoue, T., and Stern-
berg, P. W. (2007). The C. ele-
gans ROR receptor tyrosine kinase,
CAM-1, non-autonomously inhibits
the Wnt pathway. Development 134,
4053–4062.
Green, J. L., Kuntz, S. G., and Sternberg,
P. W. (2008). Ror receptor tyrosine
kinases: orphans no more. Trends
Cell Biol. 18, 536–544.
Hudecek, M., Schmitt, T. M., Baskar, S.,
Lupo-Stanghellini,M.T.,Nishida,T.,
Yamamoto, T. N., Bleakley, M., Tur-
tle, C. J., Chang,W. C., Greisman, H.
A.,Wood, B., Maloney, D. G., Jensen,
M. C., Rader, C., and Riddell, S. R.
(2010). The B-cell tumor-associated
antigen ROR1 can be targeted with
T cells modiﬁed to express a ROR1-
speciﬁc chimeric antigen receptor.
Blood 116, 4532–4541.
Ishitani,T.,Kishida, S.,Hyodo-Miura, J.,
Ueno, N., Yasuda, J., Waterman, M.,
Shibuya,H.,Moon, R. T.,Ninomiya-
Tsuji, J., and Matsumoto, K. (2003).
The TAK1-NLK mitogen-activated
protein kinase cascade functions
in the Wnt-5a/Ca(2+) pathway to
antagonizeWnt/beta-catenin signal-
ing. Mol. Cell. Biol. 23, 131–139.
Kani, S., Oishi, I., Yamamoto, H., Yoda,
A., Suzuki, H., Nomachi, A., Iozumi,
K., Nishita, M., Kikuchi, A., Takumi,
T., and Minami, Y. (2004). The
receptor tyrosine kinase Ror2 asso-
ciates with and is activated by casein
kinase Iepsilon. J. Biol. Chem. 279,
50102–50109.
Katoh, M. (2005). Comparative
genomics on ROR1 and ROR2
orthologs. Oncol. Rep. 14,
1381–1384.
Kaucka, M., Krejci, P., Plevova,
K., Pavlova, S., Prochazkova, J.,
Janovska, P., Valnohova, J., Kozubik,
A., Pospisilova, S., and Bryja, V.
(2011). Post-translational modiﬁ-
cations regulate signalling by Ror1.
Acta Physiol. (Oxf). 203, 351–362.
Kobayashi, M., Shibuya, Y., Takeuchi, J.,
Murata, M., Suzuki, H., Yokoo, S.,
Umeda,M.,Minami,Y., andKomori,
T. (2009). Ror2 expression in squa-
mous cell carcinoma and epithelial
dysplasia of the oral cavity. Oral
Surg. Oral Med. Oral Pathol. Oral
Radiol. Endod. 107, 398–406.
Kurban,G.,Hudon,V.,Duplan, E.,Ohh,
M., and Pause, A. (2006). Char-
acterization of a von Hippel Lin-
dau pathway involved in extracellu-
lar matrix remodeling, cell invasion,
and angiogenesis. Cancer Res. 66,
1313–1319.
Li, P., Harris, D., Liu, Z., Liu, J.,
Keating, M., and Estrov, Z. (2010).
Stat3 activates the receptor tyro-
sine kinase like orphan receptor-
1 gene in chronic lymphocytic
leukemia cells. PLoS ONE 5, e11859.
doi:10.1371/journal.pone.0011859
Liu, Y., Rubin, B., Bodine, P. V., and
Billiard, J. (2008). Wnt5a induces
homodimerization and activation of
Ror2 receptor tyrosine kinase. J. Cell.
Biochem. 105, 497–502.
Lyashenko, N, Weissenböck, M., Sharir,
A., Erben, R. G., Minami, Y., and
Hartmann, C. (2010). Mice lack-
ing the orphan receptor ror1 have
distinct skeletal abnormalities and
are growth retarded. Dev. Dyn. 239,
2266–2277.
Maeda, K., Kobayashi, Y., Udagawa, N.,
Uehara, S., Ishihara, A., Mizoguchi,
T., Kikuchi, Y., Takada, I., Kato,
S., Kani, S., Nishita, M., Marumo,
K., Martin, T. J., Minami, Y.,
and Takahashi, N. (2012). Wnt5a-
Ror2 signaling between osteoblast-
lineage cells and osteoclast pre-
cursors enhances osteoclastogenesis.
Nat. Med. 18, 405–12.
Masiakowski, P., and Carroll, R. D.
(1992). A novel family of cell sur-
face receptors with tyrosine kinase-
like domain. J. Biol. Chem. 267,
26181–26190.
McDonald, S. L., and Silver, A. (2009).
The opposing roles of Wnt-5a in
cancer. Br. J. Cancer 101, 209–214.
Mikels, A., Minami, Y., and Nusse,
R. (2009). Ror2 receptor requires
tyrosine kinase activity to mediate
Wnt5A signaling. J. Biol. Chem. 284,
30167–30176.
Mikels, A. J., and Nusse, R. (2006).
Puriﬁed Wnt5a protein activates
or inhibits beta-catenin-TCF signal-
ing depending on receptor context.
PLoS Biol. 4, e115. doi:10.1371/jour-
nal.pbio.0040115
Minami, Y., Oishi, I., Endo, M.,
and Nishita, M. (2010). Ror-family
receptor tyrosine kinases in non-
canonicalWnt signaling: their impli-
cations in developmental morpho-
genesis and human diseases. Dev.
Dyn. 239, 1–15.
Morioka, K., Tanikawa, C., Ochi, K.,
Daigo, Y., Katagiri, T., Kawano,
H., Kawaguchi, H., Myoui, A.,
Yoshikawa, H., Naka, N., Araki, N.,
Kudawara, I., Ieguchi, M., Naka-
mura, K., Nakamura, Y., and Mat-
suda, K. (2009). Orphan receptor
tyrosine kinase ROR2 as a potential
therapeutic target for osteosarcoma.
Cancer Sci. 100, 1227–1233.
Nomachi, A., Nishita, M., Inaba, D.,
Enomoto, M., Hamasaki, M., and
Minami, Y. (2008). Receptor tyro-
sine kinase Ror2 mediates Wnt5a-
induced polarized cell migration by
activating c-Jun N-terminal kinase
via actin-binding protein ﬁlamin A.
J. Biol. Chem. 283, 27973–27981.
Nomi, M., Oishi, I., Kani, S., Suzuki,
H., Matsuda, T., Yoda, A., Kitamura,
M., Itoh, K., Takeuchi, S., Takeda,
K., Akira, S., Ikeya, M., Takada,
S., and Minami, Y. (2001). Loss of
mRor1 enhances the heart and skele-
tal abnormalities inmRor2-deﬁcient
mice: redundant and pleiotropic
functions of mRor1 and mRor2
receptor tyrosine kinases. Mol. Cell.
Biol. 21, 8329–8335.
O’Connell M. P., Fiori J. L., Xu M.,
Carter A. D., Frank B. P., Camilli T.
C., French A. D., Dissanayake S. K.,
Indig F. E., Bernier M., Taub D. D.,
Hewitt S. M., and Weeraratna A. T.
(2010). The orphan tyrosine kinase
receptor, ROR2, mediates Wnt5A
signaling in metastatic melanoma.
Oncogene 29, 34–44.
Oishi, I., Suzuki, H., Onishi, N.,
Takada, R., Kani, S., Ohkawara, B.,
Koshida, I., Suzuki, K., Yamada,
G., Schwabe, G. C., Mundlos,
S., Shibuya, H., Takada, S., and
Minami, Y. (2003). The receptor
tyrosine kinase Ror2 is involved
in non-canonical Wnt5a/JNK sig-
nalling pathway. Genes Cells 8,
645–654.
Oishi, I., Takeuchi, S., Hashimoto,
R., Nagabukuro, A., Ueda, T., Liu,
Z. J., Hatta, T., Akira, S., Mat-
suda, Y., Yamamura, H., Otani, H.,
and Minami, Y. (1999). Spatio-
temporally regulated expression of
receptor tyrosine kinases, mRor1,
mRor2, during mouse development:
implications in development and
function of the nervous system.
Genes Cells 4, 41–56.
Rabbani, H., Ostadkarampour, M.,
Danesh Manesh, A. H., Basiri, A.,
Jeddi-Tehrani, M., and Forouzesh,
F. (2010). Expression of ROR1 in
patients with renal cancer–a poten-
tial diagnostic marker. Iran. Biomed.
J. 14, 77–82.
Reddy, U. R., Phatak, S., Allen, C.,
Nycum, L. M., Sulman, E. P.,
White, P. S., and Biegel, J. A.
(1997). Localization of the human
Ror1 gene (NTRKR1) to chro-
mosome 1p31-p32 by ﬂuorescence
in situ hybridization and somatic
cell hybrid analysis. Genomics 41,
283–285.
Reddy, U. R., Phatak, S., and Plea-
sure, D. (1996). Human neural tis-
sues express a truncated Ror1 recep-
tor tyrosine kinase, lacking both
extracellular and transmembrane
domains. Oncogene 13, 1555–1559.
Rehn, M., Pihlajaniemi, T., Hofmann,
K., and Bucher, P. (1998). The friz-
zled motif: in how many different
protein families does it occur?Trends
Biochem. Sci. 23, 415–417.
Sadowski, I., Stone, J. C., and Pawson, T.
(1986). A noncatalytic domain con-
served among cytoplasmic protein-
tyrosine kinases modiﬁes the kinase
function and transforming activity
of Fujinami sarcoma virus P130gag-
fps. Mol. Cell. Biol. 6, 4396–4408.
Sato, A., Yamamoto, H., Sakane, H.,
Koyama, H., and Kikuchi, A. (2010).
Wnt5a regulates distinct signalling
pathways by binding to Frizzled2.
EMBO J. 29, 41–54.
Schwabe, G. C, Tinschert, S., Buschow,
C.,Meinecke, P.,Wolff, G.,Gillessen-
Kaesbach, G., Oldridge, M., Wilkie,
A. O., Kömec, R., and Mundlos, S.
(2000). Distinct mutations in the
receptor tyrosine kinase gene ROR2
cause brachydactyly type B. Am. J.
Hum. Genet. 67, 822–31.
Shabani, M., Asgarian-Omran, H., Vos-
sough, P., Shariﬁan, R. A., Fara-
noush, M., Ghragozlou, S., Khosh-
noodi, J., Roohi, A., Jeddi-Tehrani,
M., Mellstedt, H., Rabbani, H., and
Shokri, F. (2008). Expression proﬁle
of orphan receptor tyrosine kinase
(ROR1) and Wilms’ tumor gene 1
(WT1) in different subsets of B-cell
acute lymphoblastic leukemia. Leuk.
Lymphoma 49, 1360–1367.
Tassev, D. V., Cheng, M., and Che-
ung,N. K. (2012). Retargeting NK92
cells using an HLA-A2-restricted
EBNA3C-speciﬁc chimeric antigen
receptor. Cancer Gene Ther. 19,
84–100.
Uhrmacher, S., Schmidt, C., Erdfelder,
F., Poll-Wolbeck, S. J., Gehrke, I.,
www.frontiersin.org April 2012 | Volume 2 | Article 34 | 7
Rebagay et al. Targeted therapy using ROR1/ROR2
Hallek, M., and Kreuzer, K. A.
(2011). Use of the receptor tyro-
sine kinase-like orphan receptor
1 (ROR1) as a diagnostic tool
in chronic lymphocytic leukemia
(CLL). Leuk. Res. 35, 1360–1366.
van Bokhoven,H., Celli, J., Kayserili, H.,
van Beusekom, E., Balci, S., Brus-
sel, W., Skovby, F., Kerr, B., Percin,
E. F., Akarsu, N., and Brunner, H.
G. (2000). Mutation of the gene
encoding the ROR2 tyrosine kinase
causes autosomal recessive Robinow
syndrome. Nat. Genet. 25, 423–426.
Vidal, M., Gigoux, V., and Garbay, C.
(2001). SH2 and SH3 domains as
targets for anti-proliferative agents.
Crit. Rev. Oncol. Hematol. 40,
175–186.
Weaver,A.M. (2006). Invadopodia: spe-
cialized cell structures for cancer
invasion. Clin. Exp. Metastasis 23,
97–105.
Wilson, C., Goberdhan, D. C., and
Steller, H. (1993). Dror, a potential
neurotrophic receptor gene, encodes
a Drosophila homolog of the ver-
tebrate Ror family of Trk-related
receptor tyrosine kinases. Proc. Natl.
Acad. Sci. U.S.A. 90, 7109–7113.
Wright, T. M., Brannon, A. R., Gor-
dan, J. D., Mikels, A. J., Mitchell,
C., Chen, S., Espinosa, I., Van De
Rijn, M., Pruthi, R., Wallen, E.,
Edwards, L., Nusse, R., and Rath-
mell, W. K. (2009). Ror2, a devel-
opmentally regulated kinase, pro-
motes tumor growth potential in
renal cell carcinoma. Oncogene 28,
2513–2523.
Yamamoto, H., Yoo, S. K., Nishita, M.,
Kikuchi, A., and Minami, Y. (2007).
Wnt5a modulates glycogen synthase
kinase 3 to induce phosphorylation
of receptor tyrosine kinase Ror2.
Genes Cells 12, 1215–1223.
Yang, J., Baskar, S., Kwong, K. Y.,
Kennedy, M. G., Wiestner, A.,
and Rader, C. (2011). Therapeutic
potential and challenges of targeting
receptor tyrosine kinase ROR1 with
monoclonal antibodies in B-cell
malignancies. PLoS ONE 6, e21018.
doi:10.1371/journal.pone.0021018
Yoda, A., Oishi, I., and Minami, Y.
(2003). Expression and function
of the Ror-family receptor tyro-
sine kinases during development:
lessons from genetic analyses of
nematodes, mice, and humans. J.
Recept. Signal Transduct. Res. 23,
1–15.
Zhang, S., Chen, L., Cui, B., Chuang, H.
Y., Yu, J., Wang-Rodriguez, J., Tang,
L.,Chen,G.,Basak,G.W., andKipps,
T. J. (2012). ROR1 is expressed
in human breast cancer and asso-
ciated with enhanced tumor-cell
growth. PLoS ONE 7, e31127.
doi:10.1371/journal.pone.0031127
Conﬂict of Interest Statement: Dr.
Cheng Liu is founder and CEO
of Eureka Therapeutics, Inc., which
owns intellectual property and inter-
ests related to ROR1/ROR2 antibodies.
Eureka Therapeutics, Inc., could proﬁt
ﬁnancially from successful development
of ROR1/ROR2 targeted therapies. Dr.
Nai-Kong Cheung has a contractual
research relationship with Eureka Ther-
apeutics, Inc.; he owns no rights and
has no commercial interest in ROR1 or
ROR2 antibodies.
Received: 13December 2011; accepted: 22
March 2012; published online: 18 April
2012.
Citation: Rebagay G, Yan S, Liu C and
Cheung N-K (2012) ROR1 and ROR2 in
human malignancies: potentials for tar-
geted therapy. Front. Oncol. 2:34. doi:
10.3389/fonc.2012.00034
This article was submitted to Frontiers in
Cancer Molecular Targets and Therapeu-
tics, a specialty of Frontiers in Oncology.
Copyright © 2012 Rebagay, Yan, Liu
and Cheung . This is an open-access
article distributed under the terms of
the Creative Commons Attribution Non
Commercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
Frontiers in Oncology | Cancer Molecular Targets andTherapeutics April 2012 | Volume 2 | Article 34 | 8
